| Title | A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy |
| Authors | Liu, Dong Qi, Xuexiu Wei, Xiaoyi Zhao, Lijun Wang, Xuechun Li, Shuhong Wang, Zhidong Shi, Licai Xu, Jiean Hong, Mei Liu, Zhong Zhao, Lili Wang, Xiankun Zhang, Bo Zhang, Yuhan Wang, Feng Cao, Yu J. |
| Affiliation | Peking Univ, State Key Lab Chem Oncogen, Guangdong Prov Key Lab Chem Genom, Shenzhen Grad Sch, Shenzhen 518055, Guangdong, Peoples R China Lunan Pharmaceut Grp Co Ltd, Feixian 273400, Shandong, Peoples R China Natl Engn Lab High Level Express Mammalian Cells, Feixian 273400, Shandong, Peoples R China Shenzhen Bay Lab, Inst Neurol & Psychiat Disorders, Shenzhen 518132, Guangdong, Peoples R China Chinese Acad Sci, Beijing Translat Ctr Biopharmaceut Inst Biophys, Key Lab Prot & Peptide Pharmaceut, Beijing 100101, Peoples R China Shenzhen Bay Lab, Inst Chem Biol, Shenzhen 518132, Peoples R China |
| Keywords | MONOCLONAL-ANTIBODIES RATIONAL DESIGN TUMOR-CELLS DOMAIN HER2 |
| Issue Date | 2022 |
| Publisher | THERANOSTICS |
| Abstract | Rationale: T-cell-redirecting bispecific antibodies (bsAbs) and trispecific antibodies (tsAbs) designed to recognize different epitopes or antigens have emerged as promising cancer therapies. Current approaches are all designed to include another antibody specific to the site of the primary antibody, and the molecular structures are generally established. However, the dimensions of target molecule and epitope location play a key role in the efficiency of the immunological synapse (IS) formation and subsequent T-cell-redirecting activities, therefore the connection flexibility of these antibodies determines the geometries of different formats of these molecules and will have a major impact on the efficacy. Methods: We describe a novel recombination strategy using various linker designs to site-specifically fuse anti-Her2 (2Rs15) or anti-VEGFR2 (3VGR19) nanobodies to different positions of the anti-CD3 antibody fragment (Fab, SP34). Based on the comparison among the various antigen-specific bsAbs, we could determine the desired fusion site of each nanobody to SP34, and further ensure the optimal structure of tsAbs with synergistic dual-antigen enhanced T-cell-redirecting activities. Results: This approach allows precise control of the formation of IS between Her2-and/or VEGFR2-expressing cancer cells and T cells, to obtain the optimal structure of the Her2/VEGFR2/CD3 tsAb without the need to map antibody-binding epitopes. Optimization of Her2/VEGFR2/CD3 tsAb results in enhanced T-cell-redirecting in vitro and in vivo antitumor efficacy compared with the corresponding bsAbs alone or in combination, and the potency to overcome tumor relapse due to antigen escape or resistance to Herceptin and Cyramza therapy. Conclusion: The novel design strategy for developing tsAbs using a site-specific recombination approach represents a promising platform for immuno-oncology and in applications other than cancer therapy. |
| URI | http://hdl.handle.net/20.500.11897/661748 |
| ISSN | 1838-7640 |
| DOI | 10.7150/thno.75037 |
| Indexed | SCI(E) |
| Appears in Collections: | 化学生物学与生物技术学院 |
